Given the high number of both adult and pediatric AML patients harboring FLT3 mutations (7, 17) and their poor outcome, many efforts have been made to develop FLT3 targeted inhibitors, and a variety of compounds have entered clinical trials for both adult and pediatric patients (Table 1). The gene discussed is FLT3; the disease is acute myeloid leukemia.